Injectable Drug Delivery conference 2018

SMi Group16 - 17 May 2018, London, UK.
The SMi Group are thrilled to present the launch of Injectable Drug Delivery Conference 2018. The event is taking place in central London on 16th and 17th May 2018, with two pre-conference workshops occurring on 15th May 2018.

The Global Injectable Drug Delivery Market is expected to reach $789.7 billion USD by 2024, with a compound annual growth rate (CAGR) of 11.5% during the period of 2017 to 2024, according to Research Markets Reports. Therefore, this conference will aim to discuss the key developments in this field and the latest technological advancements.

How Will You Benefit?

Network and learn from leading professionals such as:

Chairs for 2018:

  • Jean-René Authelin, Global Head, Pharmaceutical Engineering, Sanofi
  • Joel Richard, Senior Vice President, Peptides Development, Ipsen

Featured speakers:

  • Anand Subramony, Vice President, Novel Product Technologies, MedImmune
  • Mostafa Nakach, Head of Pharmaceutical Engineering, Sanofi
  • Maxime Gaillot, Senior Device Engineer, Roche
  • Pierre Goldbach, Senior Principal Scientist, Late-Stage Pharmaceutical and Processing Development, F. Hoffmann-La Roche AG
  • Fie Falck Larsen, Senior Usability Engineer, Injection Devices, Global Research and Development, LEO Pharma
  • Francesco Malavasi, Medical Device Quality Device Risk Manager, Novartis

Featured highlights:

  • Review device designs for a future portfolio
  • Explore risk management options for combination products
  • Hear how companies are tackling compatibility challenges of biologics with high volume injectors
  • Learn how vial-based novel delivery technologies can overcome complex dosing regiments
  • Discover how nanosystems can help address present and future challenges in injectable peptide delivery

View the full agenda online.

Early-Bird Rates

  • Book by 31st January and save £400
  • Book by 28th February and save £200
  • Book by 29th March and save £100

For further information and to register, please visit:
http://www.smi-online.co.uk/pharmaceuticals/uk/injectable-drug-delivery

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

SK bioscience and GSK start Phase 3 trial of adjuv…

SK bioscience (SK) and GlaxoSmithKline plc (GSK) today announced the initiation of a Phase 3 clinical study of SK's COVID-19 vaccine candidate, GBP510, in combination wit...

Blood vessels produce growth factor that promotes …

Blood vessels supply tumors with nutrients and, on the other hand, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a dista...

No serious health effects linked to mRNA COVID-19 …

Federal and Kaiser Permanente researchers combing the health records of 6.2 million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 v...

First-in-human clinical trial for a vaccine to tre…

The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use disorder developed by resear...

New study examines 'Achilles heel' of cancer tumou…

Researchers at the University of British Columbia's faculty of medicine and BC Cancer Research Institute have uncovered a weakness in a key enzyme that solid tumour cance...

AI algorithm solves structural biology challenges

Determining the 3D shapes of biological molecules is one of the hardest problems in modern biology and medical discovery. Companies and research institutions often spend ...

A drug costing less than €2 a day helps in the tre…

Metoprolol, a drug widely used to treat cardiovascular disease, is beneficial when administered to COVID-19patients. This is the finding of a study by investigators at th...

Sandoz strengthens pipeline by entering into agree…

Sandoz, a Novartis division, today announced that it has entered into a commercialization agreement with Bio-Thera Solutions, Ltd. for biosimilar bevacizumab (BAT1706). B...

Pfizer and BioNTech submit a variation to EMA with…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that they submitted a variation to the European Medicines Agency (EMA) requesting to update the Condition...

Rheumatoid arthritis treated with implanted cells …

With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically ...

One in three Americans had COVID-19 by the end of …

A new study published in the journal Nature estimates that 103 million Americans, or 31 percent of the U.S. population, had been infected with SARS-CoV-2 by the end of 20...

NIH scientists build a cellular blueprint of multi…

Chronic lesions with inflamed rims, or "smoldering" plaques, in the brains of people with multiple sclerosis (MS) have been linked to more aggressive and disabling forms ...